In this pilot study, we have demonstrated that ARCA can be used to detect differential levels of CD34+VEGFR-2+CD45– EPCs in patients with NNV-ARMD and compared with NV-ARMD (p = 0.17), although future studies will be needed to confirm these results. This evidence concerns the gene CD34 and age-related macular degeneration.